<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01630031</url>
  </required_header>
  <id_info>
    <org_study_id>1</org_study_id>
    <nct_id>NCT01630031</nct_id>
  </id_info>
  <brief_title>Contact Force Sensing and Pulmonary Vein Isolation</brief_title>
  <official_title>Pulmonary Vein Isolation: Interest of Real-Time Contact Force Sensing During Radiofrequency Catheter Ablation for Paroxysmal Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinique Pasteur</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinique Pasteur</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction - Pulmonary vein isolation (PVI) is the cornerstone of paroxysmal atrial&#xD;
      fibrillation (AF) ablation. Recurrences remain, however, not infrequent and are mainly due to&#xD;
      PVs reconnection. In this setting, all procedural means able to improve the quality of tissue&#xD;
      lesions are welcome.&#xD;
&#xD;
      Study Hypothesis - A continuous sensing of contact force (CF) during ablation, offered by a&#xD;
      new catheter available on the market, was a valuable additional tool increasing the efficacy&#xD;
      of the ablation procedure for PVI.&#xD;
&#xD;
      Methods - Prospective observational non-randomized monocentric study. Patients with&#xD;
      paroxysmal AF receive PVI following standard ablation procedures (linear antral catheter&#xD;
      ablation guided by CARTO 3 System, Biosense Webster, Inc.) using either a new irrigated RF&#xD;
      ablation catheter that provides tip-to-tissue CF information (THERMOCOOL SMARTTOUCH Catheter,&#xD;
      Biosense Webster, Inc.) (CF group), or a non-CF irrigated catheter (THERMOCOOL SF or EZ STEER&#xD;
      THERMOCOOL Catheter, Biosense Webster, Inc.) (control group). Overall, 60 consecutive&#xD;
      patients are enrolled in the study, with 30 patients in each group. All procedures is&#xD;
      performed by the same experienced operator, not blinded to the catheter used. Except for CF&#xD;
      information (with an objective of at least 10 g, associated to the most perpendicular vector&#xD;
      obtainable), ablation procedures are carried out using identical approaches in both groups.&#xD;
      Patients are discharged from hospital free of antiarrhythmic therapy. Patients are enrolled&#xD;
      in a specific follow-up plan.&#xD;
&#xD;
      Primary Endpoints -(1) Proportion of PVI after exclusive anatomic approach, (2) Proportion of&#xD;
      patients free of AF after 12-month follow-up.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">November 2012</completion_date>
  <primary_completion_date type="Anticipated">November 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of PVI after exclusive anatomic approach</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients free of AF after 12-month FU</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total time of fluoroscopy and radiation exposure</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total time of RF application required for completed PVI</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of pericardial effusion at echocardiography</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <condition>Catheter Ablation</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Use of the THERMOCOOL SF or EZ STEER THERMOCOOL Catheter, Biosense Webster, Inc.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CF group</arm_group_label>
    <description>Use of THERMOCOOL SMARTTOUCH Catheter, Biosense Webster, Inc.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Study population included patients with paroxysmal atrial fibrillation who undergo a first&#xD;
        catheter ablation procedure (pulmonary vein isolation).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptomatic paroxysmal atrial fibrillation despite at least failure of one&#xD;
             anti-arrhythmic drug&#xD;
&#xD;
          -  Age 18-75 yrs&#xD;
&#xD;
          -  First catheter ablation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Left ventricle ejection fraction at echocardiography &lt;50%&#xD;
&#xD;
          -  History of heart surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Paul Albenque, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Pasteur</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>June 23, 2012</study_first_submitted>
  <study_first_submitted_qc>June 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2012</study_first_posted>
  <last_update_submitted>June 26, 2012</last_update_submitted>
  <last_update_submitted_qc>June 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinique Pasteur</investigator_affiliation>
    <investigator_full_name>JP Albenque</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>paroxysmal</keyword>
  <keyword>contact force</keyword>
  <keyword>radiofrequency</keyword>
  <keyword>catheter ablation</keyword>
  <keyword>pulmonary vein isolation</keyword>
  <keyword>recurrence</keyword>
  <keyword>follow-up</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

